Does qHPV vaccine prevent anal intraepithelial neoplasia and condylomata in men? by Shum, Johnny et al.
Evidence-based answers from the  
Family Physicians Inquiries Network
581jFPoNlINE.com Vol 64, No 9  |  SEPTEmBER 2015  |  ThE jouRNal oF FamIly PRacTIcE
clinical inquiries
EvidEncE-basEd answEr
Johnny Shum, DO;  
Gary Kelsberg, MD 
Valley Family Medicine  
Residency, Renton, Wash
Sarah Safranek, MLIS
University of Washington 
Health Sciences Libraries, 
Seattle
Deputy eDItOR
Rick Guthmann, MD  
Advocate Illinois Masonic 
Family Medicine Residency, 
Chicago
	 Does	qHPV	vaccine	prevent	
anal	intraepithelial	neoplasia	
and	condylomata	in	men?
	 Yes.	 Quadrivalent	 human	 papil-
	 lomavirus	 (qHPV)	vaccine	 reduces	
rates	of	anal	intraepithelial	neoplasia	(AIN)	
by	 50%	 to	 54%,	 and	persistent	 anal	 infec-
tion	by	59%,	associated	with	the	4	types	of	
HPV	 in	 the	 vaccine	 (6,	 11,	 16,	 and	 18)	 in	
young	men	who	have	sex	with	men	(MSM);	
it	 also	 reduces	 external	 genital	 lesions	 by	
66%,	and	persistent	HPV	 infection	associ-
ated	with	 the	 same	 4	HPV	 types	 by	 48	 to	
59%	 in	 all	 young	men,	heterosexual	men,	
and	 MSM	 (strength	 of	 recommendation	
[SOR]:	B,	 randomized,	placebo-controlled	
trials	[RCTs]).
In	 addition,	 the	 vaccine	 is	 associated	
with	 a	 50%	 to	 55%	 decrease	 in	 recurrent	
high-grade	 AIN	 and	 anogenital	 condylo-
mata	in	older	MSM	(SOR:	B,	cohort	studies).
evidence summary
Two	 RCTs	 that	 evaluated	 qHPV	 in	 young	
men	 for	 preventing	 outcomes	 associated	
with	the	4	HPV	subtypes	in	the	vaccine	(6,	11,	
16,	and	18)	found	that	it	reduced	them	by	50%	
to	 66%	 using	 an	 intention-to-treat	 protocol	
(tABLe1-4).	
Vaccination reduces AIN  
and persistent infection in MSM
The	first	RCT	evaluated	a	subset	of	602	MSM	
from	 the	 second,	 larger	 RCT	 for	 prevent-
ing	 AIN	 and	 persistent	 HPV	 infection.1	The	
intention-to-treat	 population	 included	 men	
with	5	or	 fewer	 lifetime	sexual	partners	who	
had	engaged	in	insertive	or	receptive	anal	in-
tercourse	or	oral	sex	within	the	last	year,	were	
not	necessarily	HPV-negative	 at	 enrollment,	
and	received	at	least	one	dose	of	vaccine	(or	
placebo).	
The	 vaccine	 reduced	 AIN	 associated	
with	 the	4	HPV	types	(6.3	vs	12.6	events	per	
100	 person-years;	 relative	 risk	 reduction	
[RRR]=50.3%;	 95%	 confidence	 interval	 [CI],	
25.7-67.2;	number	needed	to	treat	[NNT]=16	
to	 prevent	 one	 AIN	 case	 per	 year)	 and	
with	HPV	of	any	 type	 (13	vs	17.5	events	per	
100	 person-years;	 RRR=25.7%;	 95%	 CI,	 -1.1	
to	45.6).	It	also	reduced	the	rate	of	persistent	
HPV	 infection	with	 the	 4	HPV	 vaccine	 sub-
types (8.8	vs	21.6	events	per	100	person-years;	
RRR=59.4%;	95%	CI,	43%-71%;	NNT=8	to	pre-
vent	one	persistent	HPV	infection	per	year).	
Investigators	in	the	study	also	evaluated	
vaccine	efficacy	in	a	smaller	subset	(194	men)	
using	per-protocol	analysis	and	found	higher	
prevention	 rates	 (78%	 for	 AIN	 due	 to	 HPV	
types	6,	11,	16,	and	18).	Investigators	followed	
these	subjects	every	6	months	for	36	months	
with	 polymerase	 chain	 reaction	 testing	 for	
HPV	 DNA,	 high-resolution	 anoscopy	 with	
anal	cytology,	and	anal	biopsy	and	histology	
if	there	were	atypia.	
the vaccine decreases persistent HpV 
infection and external genital lesions
The	 second	 RCT,	 including	 both	 MSM	 and	
heterosexual	men,	 found	that	qHPV	vaccine	
reduced	rates	of	persistent	HPV	infection	by	
48%,	 and	 external	 genital	 lesions	 (condylo-
mata	 or	 intraepithelial	 neoplasia	 involving	
the	 penis,	 perineum,	 or	 perianal	 area)	 by	
66%	associated	with	HPV	types	6,	11,	16,	and	
18	using	the	intention-to-treat	protocol.2	
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tABLe
HPV	vaccine	in	men:	What	the	studies	show
outcomes  
evaluated
Type of study Population outcomes Data analysis, 
by protocol 
type
Results  
(reduction com-
pared to placebo)
comments
aIN and persistent 
hPV infection 
associated with 
hPV types 6, 11, 
16, and 18
Placebo-
controlled 
double-blind 
RcT1
602 mSm, 
ages 16-25 yr
aIN grades 1, 
2, and 3 
ITT 50.3% (95% cI, 
25.7%-67.2%)
PP group (n=194) 
included only 
men who tested 
negative for hPV 
before vaccination 
(serum, anal 
cytology, anal 
biopsies), who 
were proven to 
have received all 
vaccine doses, 
and who had 5 
or fewer lifetime 
sexual partners
PP 77.5% (95% cI, 
39.6%-93.3%)
aIN grades 2 
and 3 
ITT 54.2% (95% cI, 
18%-75.3%)
PP 74.9% (95% cI, 
8.8%-95.4%)
Persistent 
anal hPV 
infection 
ITT 59.4% (95% cI, 
43%-71.4%)
PP 94.9% (95% cI, 
80.4%-99.4%)
External 
genital lesions 
(condylomata and 
intraepithelial 
neoplasia in 
genital area) 
and persistent 
hPV infection 
associated with 
hPV types 6, 11, 
16, and 18
Placebo-
controlled 
double-blind 
RcT2
4065 males, 
ages 16-26 yr
External 
genital lesions
ITT 65.5% (95% cI, 
45.8%-78.6%)
PP group (n=2805) 
met same criteria 
as in previous 
trial1 
PP 90.4% (95% cI, 
69.2%-98.1%)
Persistent 
anal hPV 
infection with 
types 6, 11, 
16, and 18
ITT 47.8% (95% cI, 
36%–57.6%)
PP 85.6% (95% cI, 
73.4%–92.9%) 
Recurrence of 
high-grade aIN 
(unspecified hPV 
type) after qhPV 
vaccination vs no 
vaccination
Nonconcurrent 
cohort3
202 mSm, 
ages 20-79 
yr (mean 
40 yr), with 
previously 
treated 
high-grade 
aIN
12/88 (13.6%) 
high-grade  
aIN 
recurrence, 
vaccinated 
men
Not 
applicable
qhPV associated 
with decreased 
recurrence risk of 
high-grade aIN;
hR=0.50 (95% cI, 
0.26-0.98; P=.04)
Subset with  
high-grade aIN 
recurrence hPV 
types 6,11,16, 
and 18: qhPV 
associated 
with decreased 
recurrence risk
hR=0.47 (95% cI, 
0.22-1.04; P=.05)
35/114 
(30.7%) high-
grade aIN 
recurrence, 
unvaccinated 
men
External genital 
lesions (anal 
condylomata), 
unspecified hPV 
type
cohort, 
vaccinated and 
unvaccinated 
with qhPV4
313 mSm,  
mean age 42 
yr, followed 
for  981 days
Development 
of anal 
condylomata, 
either new or 
recurrent
ITT Vaccinated 8.6% 
(3.7 per 100 
person-years)
hR=0.45 (95% cI, 
0.22-0.92)
 
unvaccinated 
18.8% (7.3 per 100 
person-years)
aIN, anal intraepithelial neoplasia; cI, confidence interval; hPV, human papillomavirus; hR, hazard ratio; ITT, intention to treat analysis; mSm, men who have 
sex with men; PP, per protocol analysis; qhPV, quadrivalent human papillomavirus vaccine; RcT, randomized controlled trial.
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Investigators	 used	 the	 same	 protocols	
used	 in	 the	 first	 RCT,	 and	 the	 per-protocol	
population	again	had	higher	prevention	rates	
(84%	for	any	HPV	type,	90%	against	the	4	vac-
cine	types).	The	only	adverse	effect	of	the	vac-
cine	was	injection	site	pain	(57%	vs	51%	with	
placebo;	P<.001).		
the vaccine also helps older MSM 
A	nonconcurrent	cohort	study	that	evaluated	
qHPV	 vaccination	 among	 older	 MSM	 with	
previously	 treated	 high-grade	 AIN	 found	
a	 50%	 decrease	 in	 recurrence	 rates	 in	 the	
2	 years	 after	 vaccination.3	 Investigators	 re-
cruited	 HIV-negative	 men,	 some	 of	 whom	
chose	 vaccination	 (not	 randomized),	 and	
followed	 them	 for	 2	 years.	 Study	 limitations	
included	using	medical	records	for	data	col-
lection	and	the	predominance	of	white,	non-
smoking	men	with	private	insurance.
A	post-hoc	analysis	of	older	men	with-
out	 previous	 anal	 condylomata	 (210	 men)	
or	with	 treated	 condylomata	 and	no	 recur-
rence	 in	 the	 year	 before	 vaccination	 (103	
men)	 found	 that	 qHPV	 vaccination	 was	
associated	 with	 55%	 lower	 rates	 of	 anal	
condylomata.4
Recommendations
The	Centers	for	Disease	Control	and	Preven-
tion’s	Advisory	Committee	on	Immunization	
Practices	 recommends	 routine	use	of	 qHPV	
vaccine	 in	 males	 ages	 11	 through	 21	 years,	
and	optional	use	in	unvaccinated	men	as	old	
as	26	years.5	                  JFP
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